PHD POSITION IN CANCER RESEARCH
Standort: Vienna
Art: Dissertationsstelle
Firma: Institute of Cancer Research, Department of Medicine I, Medical University of Vienna
Eingetragen am: 2020-10-05
Kontakt:
Beschreibung:

Research position: PhD thesis

 

Research Field: Cancer Research

 

Where: Institute of Cancer Research, Department of Medicine I, Medical University of Vienna

 

Contact: Wolfgang Mikulits

E-mail: wolfgang.mikulits@meduniwien.ac.at

Website: http://krebsforschung.meduniwien.ac.at/forschung-research/research-focuses/tumor-progression-and-metastasis/wolfgang-mikulits/

 

Application deadline: 30th November 2020

 

Project:

The thesis project will address the molecular collaboration of oncogenes and tumor suppressors in mouse and human liver cancer. We particularly aim at analyzing the infiltration of neutrophils and other immune cells into the tumor microenvironment and focus on their consequences in liver cancer progression and metastasis.

The project includes work with advanced cellular models, genetically engineered mouse and human liver models, CRISPR/Cas9, liver organoids, RNA-seq expression profiling, proteomics, cell imaging, immunohistochemistry.

 

We offer:

  • PhD salary for 3 - 3.5 years according to the guidelines of the FWF
  • a stimulating and dynamic scientific environment with individual supervision
  • training in the PhD excellence program IPPTO supported by the Austrian Science Fund’s doc.funds”

 

Applicants should be:

  • exceptionally motivated and talented
  • graduated (MSc) in the fields of molecular biology, cell biology, genetics, biotechnology, biochemistry or equivalent
  • experienced with standard methods of molecular and cell biology
  • excellent in scientific writing and speaking English

 

The starting point for the PhD thesis should be as soon as possible.

 

Please send your application including CV and references to wolfgang.mikulits@meduniwien.ac.at

 

About the Mikulits lab:

The laboratory focuses on the molecular mechanisms underlying the invasion and metastasis of liver carcinoma. We identified the epithelial to mesenchymal transition (EMT) of liver cancer cells and described the switch of TGF-beta from anti- to pro-oncogenic actions by the molecular cooperation with the receptor tyrosine kinase Axl (Reichl et al, Hepatology 2015; Giannelli et al, J. Hepatol. 2016; Haider et al, Hepatology 2019).

Anhang: hier